ClinicalTrials.gg
CompletedNCT01401244Updated Feb 24, 2017

Bioequivalence of Two Somatropin Products (Norditropin® Versus Genotropin®) in Healthy Adult Volunteers

A Phase 1 interventional study of somatropin and somatropin in Genetic Disorder, Prader-Willi Syndrome and Growth Disorder, sponsored by Novo Nordisk A/S. Completed at 1 site in United States. Open to participants aged 18 Years to 40 Years. Per ClinicalTrials.gov, last updated 2017-02-24.

Primary conditionPrader-Willi SyndromeRegistry: Genetic Diseases, InbornReclassifiedWhy we changed it
Registry
Genetic Diseases, Inborn — the first condition term the registry derived for this study.
ClinicalTrials.gg
Prader-Willi Syndrome
Why
  1. The study's listed conditions name Prader-Willi Syndrome, a narrower term within Genetic Diseases, Inborn.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Novo Nordisk A/S · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
18 Years to 40 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 69 studies in Prader-Willi Syndrome with a site in United States — 9 open to participants now, 14 under way, 3 of them phase 3. Prader-Willi Syndrome · United States.

Enrollment
25th of 58
30 · median 23
Started
2011
with 2 others
Phase 1
3 of 69
none open now
Registered
8th of 69
by date

Among the 69 studies in Prader-Willi Syndrome with a site in United States, this one is the 25th largest by enrollment of the 58 interventional ones that give a count, is one of 3 that started in 2011, is one of 3 in phase 1, and was the 8th registered.

Prader-Willi Syndrome

144 studies on the registry are indexed under Prader-Willi Syndrome; 23 are open to participants now.

Browse Prader-Willi Syndrome studies →

Open to participants now

9 of the 69 studies in Prader-Willi Syndrome with a site in United States are open now. Recruiting first, the newest first:

4 more — sign in →

All 9 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 16 Prader-Willi Syndrome studies recruiting now, 7 (44%) set no upper age limit and 9 (56%) stop at 75 or younger; 11 take children under 18; 1 takes healthy volunteers.

This study: 18 Years to 40 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 69 studies in Prader-Willi Syndrome with a site in United States, or all of them as a file.
02

Study summary

This trial is conducted in United States of America (USA). The aim of this trial is to examine the bioequivalence of Norditropin® versus Genotropin® in healthy adult volunteers.

03

Conditions studied

  • Genetic Disorder
  • Prader-Willi Syndrome
  • Growth Disorder
  • Idiopathic Short Stature
  • Healthy

Browse trials for

04

In context

Prader-Willi Syndrome Reclassified

144 studies on the registry are indexed under Prader-Willi Syndrome; 23 are open to participants now.

This study's enrollment of 30 is close to the median of 30 across 100 interventional studies indexed under Prader-Willi Syndrome.

Browse Prader-Willi Syndrome studies →

Lead sponsor

Novo Nordisk A/S is the lead sponsor of 1,408 studies on the registry; 105 are open to participants now.

Of its 205 completed or terminated interventional studies of FDA-regulated products, 101 (49%) have results posted.

Compared within Prader-Willi Syndrome, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Genetic Diseases, Inborn. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years to 40 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • (BMI) 18.0-27.0 kg/m\^2 (both inclusive)
  • Considered generally healthy upon completion of medical history, physical examination, vital signs, screening laboratory results, and (ECG), as judged by the Investigator (trial physician)

Exclusion criteria

Exclusion Criteria:

  • The receipt of any medicinal product within 1 month prior to this trial
  • Current or previous treatment with growth hormone or IGF-I (insulin-like growth factor-I)
  • Female of who is pregnant, breast-feeding or intends to become pregnant or is not using adequate methods (adequate contraceptive measures as required by local law or practice) for the duration of the trial
  • Known presence or history of
  • Diabetes mellitus
  • Use of pharmacologic doses of
  • Use of anabolic steroids
  • History of drug or alcohol abuse
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

06

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
30 participants (actual)

Study arms

  • Experimental
    Norditropin®

    Drug: somatropin

  • Active comparator
    Genotropin®

    Drug: somatropin

Interventions

  • A single dose 4.0 mg administered subcutaneously (under the skin) via Norditropin® FlexPro® pen

  • A single dose 4.0 mg administered subcutaneously (under the skin) via Genotropin® Pen 12

07

What researchers measure

Primary outcomes

  1. Area under the serum hGH (human growth hormone) concentration-time curve

    Time frame: from 0 to the time of the last quantifiable concentration over a 24-hour sampling period

  2. Maximum observed serum hGH concentration

    Time frame: over a 24-hour sampling period

Secondary outcomes

  1. Area under the effect (IGF-I) curve

    Time frame: from time 0 to the time of the last concentration (AUEC0-t) over a 96-hour sampling period

  2. Maximum IGF-I effect (Emax)

    Time frame: over a 96-hour sampling period

  3. The frequency of adverse events (AE)

    Time frame: from screening (3-14 days before first dose of trial product) to follow-up period (day 17 after first dose of trial product)

  4. The frequency of injection site reaction

    Time frame: from the time of injection of the trial product (day 1 and 13, respectively) to follow-up during the two dosing periods (day 5 and 17, respectively)

  5. Abnormal hematology laboratory parameters

    Time frame: from screening (3-14 days before first dose of trial product) to follow-up period (day 17 after first dose of trial product)

  6. Abnormal biochemistry laboratory parameters

    Time frame: from screening (3-14 days before first dose of trial product) to follow-up period (day 17 after first dose of trial product)

  7. Abnormal findings in physical examinations

    Time frame: from screening (3-14 days before first dose of trial product) to follow-up period (day 17 after first dose of trial product)

  8. Vital signs

    Time frame: from screening (3-14 days before first dose of trial product) to follow-up period (day 17 after first dose of trial product)

08

Study locations

1 site
  • Novo Nordisk Investigational Site
    Evansville, Indiana 47710, United States
09

References and documents

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2011 to primary completion in Sep 2011, 2 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 20, 2011
First posted
Jul 25, 2011
StartActual
Jul 14, 2011
Primary completionActual
Sep 27, 2011
CompletionActual
Sep 27, 2011
Last update
Feb 24, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 24, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01401244
Lead sponsor
Novo Nordisk A/S
Responsible party
Sponsor
First posted
Jul 25, 2011
Start date
Jul 14, 2011
Primary completion
Sep 27, 2011
Completion
Sep 27, 2011
Last update
Feb 24, 2017

Study contacts

Global Clinical Registry (GCR, 1452)
study director · Novo Nordisk A/S

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Human Growth Hormone

Start the discussion